Rationale and Protocol of AIRC IG-13218, Short-Term Radiotherapy for Early Prostate Cancer with Concomitant Boost to the Dominant Lesion. Issue 5 (September 2016)

• Record Type: Journal Article
• Authors: Timon, Giorgia; Ciardo, Delia; Bazani, Alessia; Garioni, Maria; Maestri, Davide; De Lorenzo, Daniela; Pansini, Floriana; Cambria, Raffaella; Rondi, Elena; Cattani, Federica; Marvaso, Giulia; Zerini, Dario; Vischioni, Barbara; Ciocca, Mario; Russo, Stefania; Molinelli, Silvia; Golino, Federica; Scroffi, Valerio; Rojas, Damaris P.; Fodor, Cristiana; Petralia, Giuseppe; Santoro, Luigi; De Cobelli, Ottavio; Orecchia, Roberto; Jereczek-Fossa, Barbara A.
• Is Part Of: Tumori. Volume 102:Issue 5(2016)
• Page Start: 536
• Page End: 540
• Publication Date: 2016-09
• Subjects: Biomarkers -- Dominant intraprostatic lesion (DIL) -- High-precision radiotherapy -- Hypofractionated radiotherapy -- Magnetic resonance imaging (MRI) -- Prostate cancer; Cancer -- Periodicals; 616.994
• DOI: 10.5301/tj.5000547
• Languages: English
• ISSNs: 0300-8916

Abstract

Introduction: Of the different treatments for early prostate cancer, hypofractionated external-beam radiotherapy is one of the most interesting and studied options. Methods: The main objective of this phase II clinical study is to evaluate the feasibility, in terms of the incidence of acute side effects, of a new ultra-hypofractionated scheme for low- or intermediate-risk prostate cancer patients treated with the latest imaging and radiotherapy technology, allowing dose escalation to the dominant intraprostatic lesion identified by multiparametric magnetic resonance imaging. Secondary endpoints of the study are the evaluation of the long-term tolerability of the treatment in terms of late side effects, quality of life, and efficacy (oncological outcome). Results: The study is ongoing, and we expect to complete recruitment by the end of 2016. Conclusions: Like in previous studies, we expect ultra-hypofractionated radiation treatment for prostate cancer to be well tolerated and effective. Trial registration: ClinicalTrials.gov identifier: NCT01913717.